The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo.

5-HT1 receptors are members of the G-protein-coupled receptor superfamily and are negatively linked to adenylyl cyclase activity. The human 5-HT1B and 5-HT1D receptors (previously known as 5-HT1Dbeta and 5-HT1Dalpha, respectively), although encoded by two distinct genes, are structurally very similar. Pharmacologically, these two receptors have been differentiated using nonselective chemical tools such as ketanserin and ritanserin, but the absence of truly selective agents has meant that the precise function of the 5-HT1B and 5-HT1D receptors has not been defined. In this paper we describe how, using computational chemistry models as a guide, the nonselective 5-HT1B/5-HT1D receptor antagonist 4 was structurally modified to produce the selective 5-HT1B receptor inverse agonist 5, 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6, 7-tetrahydrospiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289). This compound is a potent antagonist of terminal 5-HT autoreceptor function both in vitro and in vivo.

Review of the health of children in one-parent families.

The evidence from the few published studies concerning the physical health of children in one-parent families, suggests that these children have both a higher rate of hospitalization and a higher consulting rate with their general practitioner than two-parent children. There is also an indication that children in one-parent families suffer more health problems in the home than children in two-parent families. However, the studies that have been reviewed provide neither detailed nor confirmed results and at present the character of child health in one-parent families remains uncertain.

An approach to improving multiple alignments of protein sequences using predicted secondary structure.

The object of this work was to improve multiple sequence alignments using public-domain software and methods as far as possible. A method is described where the secondary structure of proteins is predicted and this information, coupled with a simplified description of the amino acids, is used to produce multiple sequence alignments. This method improved the accuracy of the resulting alignments by between 5 and 14% when compared with full sequence profile alignments (as scored against structural alignments). These improved alignments were used to predict the secondary structure of the sequences they contain. The resultant predictions were more accurate than those produced from less optimal alignments. An improvement of 6% for a three-state (helix, sheet and coil) prediction was observed when using the best alignment from the method presented here and the alignment obtained using sequence only. The method makes use of public domain software and all the associated files required to repeat the work are available from the primary author.

Phenyl benzenesulfonamides are novel and selective 5-HT6 antagonists: identification of N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide (SB-357134).

Substituted N-phenyl-4-methoxy-3-piperazin-1-ylbenzenesulfonamides and conformationally restricted analogues have been identified as high affinity and selective 5-HT6 antagonists. Compounds from this series had a range of pharmacokinetic profiles in rat and in general there was a correlation between clearance and CNS penetration. Based on its overall biological profile 2 (SB-357134) was selected for further pre-clinical evaluation.